Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells DJ Hazuda, P Felock, M Witmer, A Wolfe, K Stillmock, JA Grobler, ... Science 287 (5453), 646-650, 2000 | 1482 | 2000 |
Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. MD Miller, MS Krangel Critical reviews in immunology 12 (1-2), 17-46, 1992 | 1032 | 1992 |
Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition MD Miller, CM Farnet, FD Bushman Journal of virology 71 (7), 5382-5390, 1997 | 984 | 1997 |
Raltegravir with optimized background therapy for resistant HIV-1 infection RT Steigbigel, DA Cooper, PN Kumar, JE Eron, M Schechter, M Markowitz, ... New England Journal of Medicine 359 (4), 339-354, 2008 | 907 | 2008 |
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised … JL Lennox, E DeJesus, A Lazzarin, RB Pollard, JVR Madruga, DS Berger, ... The Lancet 374 (9692), 796-806, 2009 | 740 | 2009 |
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection DA Cooper, RT Steigbigel, JM Gatell, JK Rockstroh, C Katlama, P Yeni, ... New England Journal of Medicine 359 (4), 355-365, 2008 | 605 | 2008 |
Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of … M Markowitz, BY Nguyen, E Gotuzzo, F Mendo, W Ratanasuwan, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 46 (2), 125-133, 2007 | 530 | 2007 |
A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase DJ Hazuda, NJ Anthony, RP Gomez, SM Jolly, JS Wai, L Zhuang, ... Proceedings of the National Academy of Sciences 101 (31), 11233-11238, 2004 | 417 | 2004 |
Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques DJ Hazuda, SD Young, JP Guare, NJ Anthony, RP Gomez, JS Wai, ... Science 305 (5683), 528-532, 2004 | 379 | 2004 |
Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs C Katlama, SG Deeks, B Autran, J Martinez-Picado, J Van Lunzen, ... The Lancet 381 (9883), 2109-2117, 2013 | 376 | 2013 |
Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2 … JJ Eron, B Young, DA Cooper, M Youle, E DeJesus, ... The Lancet 375 (9712), 396-407, 2010 | 363 | 2010 |
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1–infected patients: final 5-year results from … JK Rockstroh, E DeJesus, JL Lennox, Y Yazdanpanah, MS Saag, H Wan, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 63 (1), 77-85, 2013 | 303 | 2013 |
Raltegravir versus efavirenz regimens in treatment-naive HIV-1–infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses JL Lennox, E DeJesus, DS Berger, A Lazzarin, RB Pollard, JVR Madruga, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 55 (1), 39-48, 2010 | 297 | 2010 |
Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail DJ Wyma, J Jiang, J Shi, J Zhou, JE Lineberger, MD Miller, C Aiken Journal of virology 78 (7), 3429-3435, 2004 | 259 | 2004 |
Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency P Ingallinella, E Bianchi, NA Ladwa, YJ Wang, R Hrin, M Veneziano, ... Proceedings of the National Academy of Sciences 106 (14), 5801-5806, 2009 | 239 | 2009 |
CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells II Singer, S Scott, DW Kawka, J Chin, BL Daugherty, JA DeMartino, ... Journal of virology 75 (8), 3779-3790, 2001 | 226 | 2001 |
Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial JJ Eron, JK Rockstroh, J Reynes, J Andrade-Villanueva, ... The Lancet infectious diseases 11 (12), 907-915, 2011 | 225 | 2011 |
Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways S Fransen, S Gupta, R Danovich, D Hazuda, M Miller, M Witmer, ... Journal of virology 83 (22), 11440-11446, 2009 | 211 | 2009 |
The human cytokine I-309 is a monocyte chemoattractant. MD Miller, MS Krangel Proceedings of the National Academy of Sciences 89 (7), 2950-2954, 1992 | 205 | 1992 |
Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino) thien-2-yl]-2, 4-dioxobutanoic acid CA Shaw-Reid, V Munshi, P Graham, A Wolfe, M Witmer, R Danzeisen, ... Journal of Biological Chemistry 278 (5), 2777-2780, 2003 | 199 | 2003 |